We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase II.
- Abstract
Presents clinical trials news, compiled as of October 2005. Letter received by CytRx Corp. from the United States Food and Administration explaining its requirements for lifting a clinical hold of the trial; Results from a Phase II trial of ZymoGenetics Inc.'s recombinant human thrombin; Preparations of Bayer Healthcare LLC for a Phase III trial after obtaining promising safety and efficacy results from randomized Phase II trials with its direct Factor XA inhibitor BAY 59-7939 for prevention of venous thromboembolism.
- Subjects
CLINICAL trials; CLINICAL medicine research; LADRX Corp.; UNITED States. Food &; Drug Administration; ZYMOGENETICS Inc.; BAYER HealthCare LLC
- Publication
Applied Clinical Trials, 2005, Vol 14, Issue 10, p19
- ISSN
1064-8542
- Publication type
Article